SWI by 7T MR Imaging for the Microscopic Imaging Diagnosis of Astrocytic and Oligodendroglial Tumors

References

1. 1.↵
   1. Ohgaki H,
   2. Kleihues P

   . Genetic profile of astrocytic and oligodendroglial gliomas. Brain Tumor Pathol 2011;28:177–83 doi:10.1007/s10014-011-0029-1 pmid:21442241

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Zhao K,
   2. Sun G,
   3. Wang Q, et al

   . The diagnostic value of conventional MRI and CT features in the identification of the IDH1-mutant and 1p/19q co-deletion in WHO grade II gliomas. Acad Radiol 2021;28:e189–98 doi:10.1016/j.acra.2020.03.008 pmid:32359929

   CrossRefPubMed
3. 3.↵
   1. Broen MP,
   2. Smits M,
   3. Wijnenga MM, et al

   . The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma: a validation study. Neuro Oncol 2018;20:1393–99 doi:10.1093/neuonc/noy048 pmid:29590424

   CrossRefPubMed
4. 4.↵
   1. Cha S,
   2. Tihan T,
   3. Crawford F, et al

   . Differentiation of low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging. AJNR Am J Neuroradiol 2005;26:266–73 pmid:15709123

   PubMedWeb of Science
5. 5.↵
   1. Yoon HJ,
   2. Ahn KJ,
   3. Lee S, et al

   . Differential diagnosis of oligodendroglial and astrocytic tumors using imaging results: the added value of perfusion MR imaging. Neuroradiology 2017;59:665–75 doi:10.1007/s00234-017-1851-x pmid:28550465

   CrossRefPubMed
6. 6.↵
   1. Chawla S,
   2. Oleaga L,
   3. Wang S, et al

   . Role of proton magnetic resonance spectroscopy in differentiating oligodendrogliomas from astrocytomas. J Neuroimaging 2010;20:3–8 doi:10.1111/j.1552-6569.2008.00307.x pmid:19021846

   CrossRefPubMed
7. 7.↵
   1. Zhang S,
   2. Chiang GC,
   3. Magge RS, et al

   . MRI based texture analysis to classify low grade gliomas into astrocytoma and 1p/19q codeleted oligodendroglioma. Magn Reson Imaging 2019;57:254–58 doi:10.1016/j.mri.2018.11.008 pmid:30465868

   CrossRefPubMed
8. 8.↵
   1. Shofty B,
   2. Artzi M,
   3. Ben Bashat D, et al

   . MRI radiomics analysis of molecular alterations in low-grade gliomas. Int J Comput Assist Radiol Surg 2018;13:563–71 doi:10.1007/s11548-017-1691-5 pmid:29270916

   CrossRefPubMed
9. 9.↵
   1. Choi C,
   2. Ganji SK,
   3. DeBerardinis RJ, et al

   . 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med 2012;18:624–29 doi:10.1038/nm.2682 pmid:22281806

   CrossRefPubMed
10. 10.↵
    1. Natsumeda M,
    2. Igarashi H,
    3. Nomura T, et al

    . Accumulation of 2-hydroxyglutarate in gliomas correlates with survival: a study by 3.0-Tesla magnetic resonance spectroscopy. Acta Neuropathol Commun 2014;2:158 doi:10.1186/s40478-014-0158-y pmid:25376594

    CrossRefPubMed
11. 11.↵
    1. Natsumeda M,
    2. Motohashi K,
    3. Igarashi H, et al

    . Reliable diagnosis of IDH-mutant glioblastoma by 2-hydroxyglutarate detection: a study by 3-T magnetic resonance spectroscopy. Neurosurg Rev 2018;41:641–47 doi:10.1007/s10143-017-0908-y pmid:28956184

    CrossRefPubMed
12. 12.↵
    1. Branzoli F,
    2. Pontoizeau C,
    3. Tchara L, et al

    . Cystathionine as a marker for 1p/19q codeleted gliomas by in vivo magnetic resonance spectroscopy. Neuro Oncol 2019;21:765–74 doi:10.1093/neuonc/noz031 pmid:30726924

    CrossRefPubMed
13. 13.↵
    1. Duyn JH,
    2. van Gelderen P,
    3. Li TQ, et al

    . High-field MRI of brain cortical substructure based on signal phase. Proc Natl Acad Sci U S A 2007;104:11796–801 doi:10.1073/pnas.0610821104 pmid:17586684

    Abstract/FREE Full Text
14. 14.↵
    1. Nakada T,
    2. Matsuzawa H,
    3. Igarashi H, et al

    . In vivo visualization of senile-plaque-like pathology in Alzheimer’s disease patients by MR microscopy on a 7T system. J Neuroimaging 2008;18:125–29 doi:10.1111/j.1552-6569.2007.00179.x pmid:18298677

    CrossRefPubMed
15. 15.↵
    1. Nakada T,
    2. Matsuzawa H,
    3. Igarashi H, et al

    . Expansion of corticomedullary junction high-susceptibility region (CMJ-HSR) with aging: a clue in the pathogenesis of Alzheimer’s disease? J Neuroimaging 2012;22:379–83 doi:10.1111/j.1552-6569.2011.00607.x pmid:21699603

    CrossRefPubMed
16. 16.↵
    1. Kabasawa H,
    2. Nabetani A,
    3. Matsuzawa H, et al

    . Imaging optimization for in-vivo human micro imaging at 7T. In: Proceedings of the International Society for Magnetic Resonance in Medicine, Vancouver, British Columbia, Canada. April 12–18, 2006
17. 17.↵
    1. Nakada T,
    2. Nabetani A,
    3. Kabasawa H, et al

    . The passage to human MR microscopy. Magn Reson Med Sci 2005;4:83–87 doi:10.2463/mrms.4.83 pmid:16340162

    CrossRefPubMed
18. 18.↵
    1. Nakada T

    . Clinical application of high and ultra-high-field MRI. Brain Dev 2007;29:325–35 doi:10.1016/j.braindev.2006.10.005 pmid:17113259

    CrossRefPubMed
19. 19.↵
    1. Reichenbach JR,
    2. Barth M,
    3. Haacke EM, et al

    . High-resolution MR venography at 3.0 Tesla. J Comput Assist Tomogr 2000;24:949–57 pmid:11105717

    CrossRefPubMed
20. 20.↵
    1. Haacke EM,
    2. Xu Y,
    3. Cheng YC, et al

    . Susceptibility weighted imaging (SWI). Magn Reson Med 2004;52:612–18 doi:10.1002/mrm.20198 pmid:15334582

    CrossRefPubMedWeb of Science
21. 21.↵
    1. Louis DN,
    2. Ohgaki H,
    3. Wiestler OD, et al

    . WHO Classification of Tumors of the Central Nervous System. International Agency for Research on Cancer; 2016
22. 22.↵
    1. Ogura R,
    2. Tsukamoto Y,
    3. Natsumeda M, et al

    . Immunohistochemical profiles of IDH1, MGMT and P53: practical significance for prognostication of patients with diffuse gliomas. Neuropathology 2015;35:324–35 doi:10.1111/neup.12196 pmid:25950388

    CrossRefPubMed
23. 23.↵
    1. Otani R,
    2. Uzuka T,
    3. Higuchi F, et al

    . IDH-mutated astrocytomas with 19q-loss constitute a subgroup that confers better prognosis. Cancer Sci 2018;109:2327–35 doi:10.1111/cas.13635 pmid:29752851

    CrossRefPubMed
24. 24.↵
    1. Zhao SS,
    2. Feng XL,
    3. Hu YC, et al

    . Better efficacy in differentiating WHO grade II from III oligodendrogliomas with machine-learning than radiologist’s reading from conventional T1 contrast-enhanced and fluid attenuated inversion recovery images. BMC Neurol 2020;20:48 doi:10.1186/s12883-020-1613-y pmid:32033580

    CrossRefPubMed
25. 25.↵
    1. De Ciantis A,
    2. Barba C,
    3. Tassi L, et al

    . 7T MRI in focal epilepsy with unrevealing conventional field strength imaging. Epilepsia 2016;57:445–54 doi:10.1111/epi.13313 pmid:26778405

    CrossRefPubMed
26. 26.↵
    1. Moenninghoff C,
    2. Kraff O,
    3. Schlamann M, et al

    . Assessing a dysplastic cerebellar gangliocytoma (Lhermitte-Duclos disease) with 7T MR imaging. Korean J Radiol 2010;11:244–48 doi:10.3348/kjr.2010.11.2.244 pmid:20191074

    CrossRefPubMed
27. 27.↵
    1. Grabner G,
    2. Kiesel B,
    3. Wohrer A, et al

    . Local image variance of 7 Tesla SWI is a new technique for preoperative characterization of diffusely infiltrating gliomas: correlation with tumour grade and IDH1 mutational status. Eur Radiol 2017;27:1556–67 doi:10.1007/s00330-016-4451-y pmid:27300198

    CrossRefPubMed
28. 28.↵
    1. Di Ieva A,
    2. God S,
    3. Grabner G, et al

    . Three-dimensional susceptibility-weighted imaging at 7 T using fractal-based quantitative analysis to grade gliomas. Neuroradiology 2013;55:35–40 doi:10.1007/s00234-012-1081-1 pmid:22903580

    CrossRefPubMedWeb of Science
29. 29.↵
    1. Frischer JM,
    2. God S,
    3. Gruber A, et al

    . Susceptibility-weighted imaging at 7 T: improved diagnosis of cerebral cavernous malformations and associated developmental venous anomalies. Neuroimage Clin 2012;1:116–20 doi:10.1016/j.nicl.2012.09.005 pmid:24179744

    CrossRefPubMed
30. 30.↵
    1. Dammann P,
    2. Wrede KH,
    3. Maderwald S, et al

    . The venous angioarchitecture of sporadic cerebral cavernous malformations: a susceptibility weighted imaging study at 7 T MRI. J Neurol Neurosurg Psychiatry 2013;84:194–200 doi:10.1136/jnnp-2012-302599 pmid:23085932

    Abstract/FREE Full Text
31. 31.↵
    1. Lupo JM,
    2. Chuang CF,
    3. Chang SM, et al

    . 7-Tesla susceptibility-weighted imaging to assess the effects of radiotherapy on normal-appearing brain in patients with glioma. Int J Radiat Oncol Biol Phys 2012;82:e493–500 doi:10.1016/j.ijrobp.2011.05.046 pmid:22000750

    CrossRefPubMed
32. 32.
    1. Bian W,
    2. Banerjee S,
    3. Kelly DA, et al

    . Simultaneous imaging of radiation-induced cerebral microbleeds, arteries and veins, using a multiple gradient echo sequence at 7 Tesla. J Magn Reson Imaging 2015;42:269–79 doi:10.1002/jmri.24802 pmid:25471321

    CrossRefPubMed
33. 33.↵
    1. Morrison MA,
    2. Mueller S,
    3. Felton E, et al

    . Rate of radiation-induced microbleed formation on 7T MRI relates to cognitive impairment in young patients treated with radiation therapy for a brain tumor. Radiother Oncol 2021;154:145–53 doi:10.1016/j.radonc.2020.09.028 pmid:32966846

    CrossRefPubMed
34. 34.↵
    1. Haacke EM,
    2. Makki M,
    3. Ge Y, et al

    . Characterizing iron deposition in multiple sclerosis lesions using susceptibility weighted imaging. J Magn Reson Imaging 2009;29:537–44 doi:10.1002/jmri.21676 pmid:19243035

    CrossRefPubMed
35. 35.
    1. Louapre C,
    2. Treaba CA,
    3. Barletta V, et al

    . Ultra-high field 7 T imaging in multiple sclerosis. Curr Opin Neurol 2020;33:422–29 doi:10.1097/WCO.0000000000000839 pmid:32657883

    CrossRefPubMed
36. 36.↵
    1. Filippi M,
    2. Evangelou N,
    3. Kangarlu A, et al

    . Ultra-high-field MR imaging in multiple sclerosis. J Neurol Neurosurg Psychiatry 2014;85:60–66 doi:10.1136/jnnp-2013-305246 pmid:23813636

    Abstract/FREE Full Text
37. 37.↵
    1. Cosottini M,
    2. Frosini D,
    3. Pesaresi I, et al

    . MR imaging of the substantia nigra at 7 T enables diagnosis of Parkinson disease. Radiology 2014;271:831–38 doi:10.1148/radiol.14131448 pmid:24601752

    CrossRefPubMed
38. 38.↵
    1. Johns SLM,
    2. Ishaque A,
    3. Khan M, et al

    . Quantifying changes on susceptibility weighted images in amyotrophic lateral sclerosis using MRI texture analysis. Amyotroph Lateral Scler Frontotemporal Degener 2019;20:396–403 doi:10.1080/21678421.2019.1599024 pmid:31025885

    CrossRefPubMed